General Psychiatry Residency Program

Prior to residency, Dr. Howe received his MD in 2020 from the McGovern Medical School at the University of Texas Health Science Center at Houston and his PhD in Neuroscience in 2018 from the MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. During his graduate studies, Dr. Howe received research funding as a pre-doctoral fellow with the American Heart Association. This funding allowed him to study the impact of TGF-signaling on reactive astrogliosis, integrin receptor expression, and basement membrane fibronectin deposition after ischemic stroke.

Dr. Howe’s research is focused on identifying novel plasma and imaging biomarkers of Alzheimer’s disease. In 2022, Dr. Howe received the Outstanding Resident Award from the National Institute of Mental Health and gave a talk on his research exploring blood biomarkers for Alzheimer’s disease. He also presented his findings on disease-modifying treatments and vascular biomarkers of cerebral amyloidosis at the Alzheimer’s Association International Conference. His presentation at the Brown University Department of Psychiatry and Human Behavior Mind Brain Research Day earned him a first-place award in the trainee category. He also presented a case related to lecanemab treatment at the Brown University Neuropathology Grand Rounds and participated as a guest host on the Bear in Mind podcast, discussing early signs of cognitive decline aimed at raising awareness in the community. Dr. Howe has 14 publications in peer-reviewed journals, with 11 as the primary author. His work covers topics from post-stroke glymphatic dysfunction to biomarkers and treatments for Alzheimer's disease. Recently, he published a review on the history, present challenges and future directions of clinical biomarkers for Alzheimer's disease (Biomarkers in Neuropsychiatry, 2023), a ground-breaking case series on amyloid-related imaging abnormalities (Journal of Prevention of Alzheimer's Disease, 2023), and contributed an editorial on treatment eligibility challenges ("Untangling Eligibility", Neurology, 2023). Currently, Dr. Howe is researching new blood tests that quantify phosphorylated tau isoforms for potential early detection and treatment. He's also seeking grants to expand this screening to underserved communities, working with local primary care clinics to augment screening for subjective cognitive decline with neuropsychiatric symptoms and accessible blood biomarkers.